Orexigen Therapeutics (Nasdaq: OREX) 28.3% HIGHER; reported Q3 EPS of $0.09, $0.22 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $30.9 million versus the consensus estimate of $8.93 million.
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) 26.1% HIGHER; announced the presentation of results from the ongoing Phase 2 study of ACH-3102 in a late breaker poster and data in three preclinical posters on ACH-3422. The poster presentations are being